These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28098761)

  • 1. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
    Ohmoto A; Rokutan H; Yachida S
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
    Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
    J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
    Klöppel G
    Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
    Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.
    Sorbye H; Baudin E; Perren A
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification.
    Lee JL; Yu CS; Kim M; Hong SM; Lim SB; Kim JC
    Surgery; 2014 Apr; 155(4):650-8. PubMed ID: 24468036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.
    Komiyama S; Okusaka T; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Sukeda A; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Hiraoka N; Shimada K
    Intern Med; 2024 Apr; 63(7):891-901. PubMed ID: 37612088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current WHO classification (2022) of neuroendocrine neoplasms].
    Buchstab O; Knösel T
    Radiologie (Heidelb); 2024 Jul; 64(7):531-535. PubMed ID: 38622292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
    Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
    Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
    Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
    Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
    De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
    J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
    Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
    Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.